Peter, B
Bibi, S
Eisenwort, G
Wingelhofer, B
Berger, D
Stefanzl, G
Blatt, K
Herrmann, H
Hadzijusufovic, E http://orcid.org/0000-0001-7409-4204
Hoermann, G
Hoffmann, T
Schwaab, J
Jawhar, M
Willmann, M
Sperr, W R
Zuber, J http://orcid.org/0000-0001-8810-6835
Sotlar, K
Horny, H-P
Moriggl, R http://orcid.org/0000-0003-0918-9463
Reiter, A
Arock, M
Valent, P
Article History
Received: 20 June 2017
Revised: 31 October 2017
Accepted: 13 November 2017
First Online: 29 November 2017
Competing interests
: GH received honoraria from Novartis and Ariad. WRS received honoraria from Novartis and Celgene, and a research grant from Lipomed. PV, H-PH and AR served as a Consultant in a global Novartis trial examining the effects of midostaurin in advanced SM. JZ received institutional support from Boehringer-Ingelheim, and is consultant and stock holder at Mirimus Inc. AR received a research grant from Novartis, honoraria from Novartis and BMS, and served in advisory boards organized by Novartis. MA received research grants from Blueprint and Deciphera, and received honoraria from Deciphera. PV received research grants from Novartis, Blueprint and Deciphera, and honoraria from Novartis, Celgene, Pfizer and Deciphera. The remaining authors declare no conflicts of interest.